Meeting
2022 ASCO Annual Meeting
Modulation of radiation biomarkers in a randomized phase II study of 131I-MIBG with or without radiation sensitizers for relapsed or refractory neuroblastoma: A report from the NANT Consortium.
Authors
Kevin M. Campbell
Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA
Kevin M. Campbell , Susan G. Groshen , Araz Marachelian , Myriam Armant , Sharmistha Pal , Daphne A. Haas-Kogan , Angela Clare Evans , Matthew A. Coleman , Julie R. Park , Meaghan Granger , Katherine K. Matthay , Steven G. DuBois
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 10026)
DOI
10.1200/JCO.2022.40.16_suppl.10026
Abstract #
10026
Poster Bd #
241
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Phase II study of 131I-MIBG with vincristine and 5 days of irinotecan for patients with relapsed or refractory neuroblastoma.
First Author: Steven G. DuBois
Poster
2023 ASCO Annual Meeting
Two schedules of vincristine, irinotecan and temozolomide (VIT) for patients with relapsed or refractory Ewing sarcoma: A randomized controlled phase 2 trial.
First Author: Jie Xu
Poster
2022 ASCO Annual Meeting
Naxitamab and granulocyte macrophage colony stimulating factor (GM-CSF) in combination with irinotecan and temozolomide in patients with high-risk neuroblastoma with primary refractory disease or in first relapse: An international, single-arm, multicenter phase 2 trial.
First Author: Godfrey Chi-Fung Chan
Poster
2022 ASCO Annual Meeting
Naxitamab-based chemoimmunotherapy for resistant high-risk neuroblastoma: Results of "HITS" phase II study.
First Author: Shakeel Modak